Today: Girls and Reality TV, Stars' Awkward Photos, Hollywood Cradle Robbers
Sorted by: Top Rated
Click to play video
Sorted by: Top Rated
No pictures yet.
Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis and liver cancer worldwide; [1] the estimated prevalence in the United States is 0.3%–0.5%. [2] Each year, approximately 11,500–13,000 persons are newly reported with ...  
From api.bing.com ()
Related news:
More perspectives...
NEW YORK (TheStreet) -- Why is everyone obsessed with hepatitis C? Initially described as "non-A/non-B," hepatitis C (HCV) didn't even have a proper name until the late 1980s, much less the rabid following the viral liver disease now enjoys in ...  
From api.bing.com ()
Related news:
More perspectives...
Local health officials urge diabetics to get the Hepatitis B vaccine. The Cerro Gordo County Department of Public Health wants diabetics to know about some new recommendations. The Advisory Committee on Immunization Practices is now recommending diabetics ...  
From api.bing.com ()
Related news:
More perspectives...
On Feb. 1, the White House Initiative on Asian Americans and Pacific Islanders expressed their commitment to ending viral hepatitis nationwide. 1 in 12 people worldwide is living with viral hepatitis, with viral hepatitis affecting as many as 5 million Americans. Hepatitis B affects 1 in...  
From asianweek.com ()
Related news:
More perspectives...
The CDC's Advisory Committee on Immunization Practices (ACIP) now recommends routine HPV vaccination for males aged 11 to 12 years and catch-up vaccination for males aged 13 to 21. These are just two of the changes to the 2012 Recommended Adult Immunization Schedule published February 1 in Annals of Internal Medicine, the flagship journal of the American College of Physicians (ACP). In addition to the changes in the HPV vaccine, the ACIP now...  
From medicalnewstoday.com ()
Related news:
More perspectives...
More From Zimbio
Zimbio Entertainment
Copyright © 2012 - Zimbio, Inc. Some rights reserved.
Share
. . .
Follow
. . .